Search This Blog

Friday, February 1, 2013

Lilly Supports the Medical Community's Testimony on the Clinical Utility of Beta-Amyloid Imaging Agents, Such as Amyvi™ (Florbetapir F 18 Injection), During CMS Public Hearing (NYSE:LLY)

Lilly Supports the Medical Community's Testimony on the Clinical Utility of Beta-Amyloid Imaging Agents, Such as Amyvi™ (Florbetapir F 18 Injection), During CMS Public Hearing (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.